Physician profile
Clark A Gray
NPI 1427141027
$12,240.96
in general payments reported to CMS, 2019-2025
41 companies · $1,497 in 2025
The $1,497 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,650 · 2020: $1,921 · 2021: $2,139 · 2022: $1,903 · 2023: $1,489 · 2024: $1,641 · 2025: $1,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,627.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,768.85 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,518.08 | 2019-2025 | |
| Novo Nordisk INC | $1,306.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,191.76 | 2019-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Pfizer INC. | $839.56 | 2019-2025 | |
| Glaxosmithkline, LLC. | $797.81 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $711.40 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $703.33 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $447.23 | 2019-2022 | |
| Amgen INC. | $342.23 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Merck Sharp & Dohme LLC | $318.27 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $199.98 | 2019-2022 | |
| Dexcom, INC. | $198.55 | 2021-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $181.95 | 2019-2023 | |
| Allergan, INC. | $178.22 | 2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clark Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.